Dose‐response curves for three promising candidates with high anti‐tumor activity and low neuronal toxicity – triptolide, doxorubicin, and daunorubicin – validated their anti‐tumor effects (reduction in GFP+ cells) and assessed their toxicity to MAP2C+ neuronal cells (Figure 1N‐P). Here, MAP2 is linked to neoplasm.